Skip to main content
Uncategorized

IRB Barcelona to collaborate with the private sector to study new painkillers for patients with arthrosis and to design diagnostic tools for other diseases

By 4 de May de 2011November 18th, 2020No Comments
< Back to news
 04.05.2011

IRB Barcelona to collaborate with the private sector to study new painkillers for patients with arthrosis and to design diagnostic tools for other diseases

Headed by Modesto Orozco, the Molecular Modelling and Bioinformatics Group at the Institute for Research in Biomedicine (IRB Barcelona) –located at the Barcelona Scientific Park– is to collaborate with the NEOGENIUS project, which involves the pharmaceutical companies Almirall, Esteve, Palau Pharma and Proteomika. This project seeks to search for new analgesics and diagnostic tools for arthrosis.


In addition to this collaboration agreement, another has been signed between IRB Barcelona, CSIC and the biotech companies Antibody Bcn and Immunostep in order to identify new protein interactions that have potential diagnostic applications. This agreement, which also involves Modesto Orozco’s lab, forms part of the EpiTag project included in the INNPACTO call, organized by the Ministry of Science and Innovation (MICINN).